| Sara Safder, MD | |
|
2125 Crystal Grove Dr, Lakeland, FL 33801-6875 | |
| (863) 688-2334 | |
| Not Available |
| Full Name | Sara Safder |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 18 Years |
| Location | 2125 Crystal Grove Dr, Lakeland, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154531887 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | ME113797 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| United Hospital Center | Bridgeport, WV | Hospital |
| Mon Health Medical Center | Morgantown, WV | Hospital |
| Davis Medical Center | Elkins, WV | Hospital |
| Summersville Regional Medical Center | Summersville, WV | Hospital |
| St Joseph's Hospital | Buckhannon, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiological Physician Associates Inc | 7719955368 | 29 |
News Archive
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
With healthcare expenses increasing by up to double digits annually and self-insured employers providing the majority of healthcare benefits for insured Americans, identifying wasted health plan expense has never been more important. A common tool for doing this is the random-sample, retrospective audit of an employee health plan's past one or two years of paid claims.
Not only that; we have also been awarded the Queen's Award for Enterprise: International Trade in recognition of our outstanding international growth. Meaning we are one of only a handful of businesses who have won multiple awards this year.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
› Verified 3 days ago
| Entity Name | Manatee Memorial Hospital L P |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770505687 PECOS PAC ID: 2062309164 Enrollment ID: O20060221000789 |
News Archive
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
With healthcare expenses increasing by up to double digits annually and self-insured employers providing the majority of healthcare benefits for insured Americans, identifying wasted health plan expense has never been more important. A common tool for doing this is the random-sample, retrospective audit of an employee health plan's past one or two years of paid claims.
Not only that; we have also been awarded the Queen's Award for Enterprise: International Trade in recognition of our outstanding international growth. Meaning we are one of only a handful of businesses who have won multiple awards this year.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
› Verified 3 days ago
| Entity Name | Radiology & Imaging Specialists Of Lakeland |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427049931 PECOS PAC ID: 2264422294 Enrollment ID: O20090306000484 |
News Archive
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
With healthcare expenses increasing by up to double digits annually and self-insured employers providing the majority of healthcare benefits for insured Americans, identifying wasted health plan expense has never been more important. A common tool for doing this is the random-sample, retrospective audit of an employee health plan's past one or two years of paid claims.
Not only that; we have also been awarded the Queen's Award for Enterprise: International Trade in recognition of our outstanding international growth. Meaning we are one of only a handful of businesses who have won multiple awards this year.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
› Verified 3 days ago
| Entity Name | Radiological Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811996960 PECOS PAC ID: 7719955368 Enrollment ID: O20150316001721 |
News Archive
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
With healthcare expenses increasing by up to double digits annually and self-insured employers providing the majority of healthcare benefits for insured Americans, identifying wasted health plan expense has never been more important. A common tool for doing this is the random-sample, retrospective audit of an employee health plan's past one or two years of paid claims.
Not only that; we have also been awarded the Queen's Award for Enterprise: International Trade in recognition of our outstanding international growth. Meaning we are one of only a handful of businesses who have won multiple awards this year.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Safder, MD 2125 Crystal Grove Dr, Lakeland, FL 33801-6875 Ph: (863) 688-2334 | Sara Safder, MD 2125 Crystal Grove Dr, Lakeland, FL 33801-6875 Ph: (863) 688-2334 |
News Archive
Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.
With healthcare expenses increasing by up to double digits annually and self-insured employers providing the majority of healthcare benefits for insured Americans, identifying wasted health plan expense has never been more important. A common tool for doing this is the random-sample, retrospective audit of an employee health plan's past one or two years of paid claims.
Not only that; we have also been awarded the Queen's Award for Enterprise: International Trade in recognition of our outstanding international growth. Meaning we are one of only a handful of businesses who have won multiple awards this year.
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.
› Verified 3 days ago
Dr. Kevin James Sawyer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2125 Crystal Grove Dr, Lakeland, FL 33801 Phone: 863-688-2334 | |
Dr. Yelena Kozirovsky, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1420 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 | |
Dr. Michael Larone Campbell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1305 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-688-2334 | |
Michael K Gordon, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2115 Crystal Grove Dr, Lakeland, FL 33801 Phone: 863-688-2334 Fax: 863-577-0303 | |
Devashri Patel, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1305 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-688-2334 | |
Alexander J Fernandez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2125 Crystal Grove Dr, Lakeland, FL 33801 Phone: 863-688-2334 | |
Jaehoon Bang, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1600 Lakeland Hills Blvd, Lakeland, FL 33805 Phone: 863-680-7000 Fax: 866-264-8519 |